Alkem Laboratories Limited
Alkem Laboratories Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹3,740 cr of revenue in its latest quarter (Q1 FY27) and kept 13.9% of sales as profit.
Healthier than 63% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 13–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 53
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in ALKEM?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 10%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹3,740 cr |
| Other Income | ₹153 cr |
| Total Income | ₹3,893 cr |
| Cost of Materials | ₹910 cr |
| Purchases of Stock-in-Trade | ₹366 cr |
| Inventory Change (±) | ₹-75 cr |
| Employee Benefit Expense | ₹809 cr |
| Finance Costs | ₹47 cr |
| Depreciation & Amortisation | ₹100 cr |
| Other Expenses | ₹964 cr |
| Total Expenses | ₹3,121 cr |
| Profit before Tax | ₹772 cr |
| Tax Expense | ₹251 cr |
| Share of JV / Associates | ₹-51 L |
| Net Profit | ₹521 cr |
| Net margin on total income | 13.4% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 3,737 cr | 3,603 cr | 3,740 cr |
| Total income | 3,880 cr | 3,803 cr | 3,893 cr |
| Expenses | 3,046 cr | 3,246 cr | 3,121 cr |
| Profit before tax | 781 cr | 423 cr | 772 cr |
| Tax | 128 cr | 171 cr | 251 cr |
| Net profit (owners' share) | 636 cr | 236 cr | 520 cr |
| Net margin (owners' share, on revenue) | 17.0% | 6.6% | 13.9% |
| EPS (₹) | 53.19 | 19.77 | 43.49 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹10 / share | 7 Aug 2026 |
| Dividend | ₹43 / share | 20 Feb 2026 |
| Dividend | ₹8 / share | 8 Aug 2025 |
| Dividend | ₹37 / share | 14 Feb 2025 |
| Dividend | ₹5 / share | 9 Aug 2024 |
| Dividend | ₹35 / share | 16 Feb 2024 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.